Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

LXRX vs DMAC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DMAC Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–3 Matrix Metrics)

DMAC Overall Winner 6-Pillar Tally: LXRX 1 – 4 DMAC (1 Tie) Matrix Metrics: LXRX 3 – 5 DMAC

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) is the stronger overall head-to-head candidate over Lexicon Pharmaceuticals, Inc. (LXRX) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). LXRX carries a Unified Composite Score of 38.7/100 (SELL) at $1.75 (N/M Forward P/E, -147.4% operating margin), whereas DMAC carries 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: LXRX is currently in a Breakdown options structure phase (RSI 54.2); meanwhile DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LXRX vs DMAC
LXRX NASDAQ
Lexicon Pharmaceuticals, Inc.
Pharmaceutical Preparations
$1.75
-2.51% 1D
Market Cap $810.3M
TTM Revenue $39M
Forward P/E N/M
Beta / 30D Vol 0.62β · 60% Vol
Unified Composite Score
38.7 / 100 SELL
Tech 5.0 Fund 33.0 Flow 65.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.2 · SMA20: $1.60 · SMA50: $1.76
DMAC NASDAQ Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.74β · 98% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 44.7 · SMA20: $9.24 · SMA50: $8.24

6-Pillar Scorecard Institutional Category Breakdown (LXRX 1 – 4 DMAC)

Columns: Metric · LXRX · DMAC
1. Valuation Multiples LXRX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 21.3x N/M
2. Growth & Scale DMAC
Revenue Growth (YoY) -20.7% +0.0%
Earnings Growth (YoY) -63.4% +0.0%
TTM Revenue (USD) $39M N/A
Market Cap $810.3M $503.1M
3. Profitability & Quality DMAC
Gross Margin 91.4% N/A
Operating Margin -147.4% 0.0%
Net Profit Margin -161.8% 0.0%
Return on Equity (ROE) -43.9% -114.6%
4. Balance Sheet & Cash Flow DMAC
Cash Generation (TTM) -$49M -$32M
Cash Flow Margin N/A N/A
Net Cash / Leverage $9.5M Net Debt (0.33x D/E) $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DMAC
Options Structure Phase BREAKDOWN SURGE
Current IV / %ile 78.4% (8th %ile) 106.3% (14th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LXRX (3) vs DMAC (5)
Institutional Metric LXRX DMAC Criterion Row Edge
Market Capitalization
Scale
$810.3M $503.1M Larger Scale LXRX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-20.7% +0.0% Higher Growth DMAC
Operating Margin (TTM)
Profitability
-147.4% 0.0% Higher Margin DMAC
Net Profit Margin
Profitability
-161.8% 0.0% Higher Margin DMAC
Return on Equity (ROE)
Capital Efficiency
-43.9% -114.6% Higher ROE LXRX
52-Week Range Position
Momentum
41% ($1–$3) 55% ($5–$11) Stronger Trend DMAC
Beta / 30D Volatility
Risk Regime
0.62β · 60% Vol 1.74β · 98% Vol Lower Realized Risk LXRX
Unified Institutional Score
Composite Signal
38.7 / 100 (SELL) 46.3 / 100 (HOLD) Higher Composite DMAC
Trailing 12M Revenue (USD)
Operating Scale
$39M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
91.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 21.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$49M ($9.5M Net Debt (0.33x D/E)) -$32M ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LXRX +3.64 pp
LXRX: +14.8% · DMAC: +11.16%
3M Horizon DMAC +55.2 pp
LXRX: -27.89% · DMAC: +27.31%
6M Horizon DMAC +66.61 pp
LXRX: -18.46% · DMAC: +48.15%
1Y Horizon DMAC +34.08 pp
LXRX: +21.18% · DMAC: +55.26%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period LXRX Revenue DMAC Revenue LXRX Op. Margin DMAC Op. Margin Margin Leader
FY2015 $130M N/A 1.1% N/A LXRX
FY2017 $20M N/A -822.1% N/A LXRX
FY2018 $30M $0M -388.5% -1352.2% LXRX
FY2019 $30M N/A 437.5% N/A LXRX
FY2020 $20M N/A -204.2% N/A LXRX
FY2023 $0M N/A -15473.0% N/A LXRX
FY2024 $10M N/A -3284.7% N/A LXRX
FY2025 $50M N/A -98.2% N/A LXRX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LXRX BREAKDOWN
98d in phase · OBV ACCUMULATION
Current IV 78.4%
IV Percentile 8th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact LXRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DMAC SURGE
8d in phase · OBV NEUTRAL
Current IV 106.3%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LXRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $810.3M market capitalization and -147.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DMAC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LXRX vs DMAC Key Questions & Quantitative Answers

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) is the stronger overall head-to-head candidate over Lexicon Pharmaceuticals, Inc. (LXRX) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). LXRX carries a Unified Composite Score of 38.7/100 (SELL) at $1.75 (N/M Forward P/E, -147.4% operating margin), whereas DMAC carries 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: LXRX is currently in a Breakdown options structure phase (RSI 54.2); meanwhile DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DMAC leads the Growth & Scale pillar: LXRX posts -20.7% YoY revenue growth and -63.4% YoY earnings growth on $39M TTM revenue (91.4% gross margin, -147.4% operating margin), compared with DMAC at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2015 to FY2025), LXRX cumulative revenue shifted -61.5% while DMAC shifted N/A. In operating R&D and SG&A reinvestment, LXRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DMAC.

LXRX screens cheaper on headline valuation multiples. LXRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 21.3x EV/Revenue (unreported FCF margin), whereas DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LXRX (-43.9% ROE) versus DMAC (-114.6% ROE) capital efficiency.

In options market volatility and institutional positioning, LXRX carries 78.4% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.62β · 60% Vol realized risk). By comparison, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.